MKT Capital Pleased with Aurinia’s Commencement of a Strategic Review Process
“We are pleased Aurinia has embraced our feedback and initiated a review of strategic alternatives.
- “We are pleased Aurinia has embraced our feedback and initiated a review of strategic alternatives.
- We are supportive of a reconstituted Board running a comprehensive process, which considers the long-term potential of the LUPKYNIS drug, to maximize value for all shareholders.
- MKT Capital has identified a highly qualified director candidate to fill one of the vacancies and we look forward to privately engaging with the Board regarding the candidacy as part of the director search process.
- From our perspective, it is imperative there are shareholder-designated directors in the boardroom to help oversee a credible, comprehensive strategic review to maximize shareholder value.